IMO I think that is the next PR I am looking forward to is when they have enrolled the first patient and when they have filled the trial. The rate of enrollment will not only speak to the awareness of its effects, but receptivity among doctors and patients.

Always look forward to more PRs about paths forward to approval and moving the company forward, but new data about LL will continue to reaffirm its safety, effectiveness, and awareness.

IMO